Our solutions address the complexities of specialty by increasing access to payers and drugs, using a high-touch, data-powered model to lower the total cost of care
Short-acting but not long-acting glucagon-like protein-1 receptor agonists are associated with increased development of GERD and Barretts esophagus: results from a global healthcare database
These results represent the greatest mean body-weight reduction reported to date for any incretin-based investigational therapy in a clinical trial of this duration.6 Although the triple-agonist mechanism offers substantial promise, glucagon receptor activation introduces theoretical safety concerns, including transient hyperglycemia, increased heart rate and potential hepatic effects
BPC157
Lastly, ongoing support and care are vital, as the best clinics provide continued monitoring and adjustments based on individual needs
Results are heterogeneous and depend on isomer composition, dose, and the population studied